AceLink Therapeutics

Private

Newark, CaliforniaHealthcare & Life Scienceshttps://acelinktherapeutics.com/

Last Round

Series A

May 1, 2021

Total Funding Raised

$10M

Company Overview

AceLink Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for diseases of glycolipid metabolism.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

substrate reduction therapySRTGCS inhibitorlysosomal storage disorderssmall molecule drugsFabry diseaseGaucher diseaserare genetic diseasesorphan drugsoral therapeuticsclinical-stage biopharmaAutosomal Dominant Polycystic Kidney DiseaseADPKDglucosylceramide synthase inhibitorglycolipid biologyNRF2 activatorParkinson's disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AceLink Therapeutics Comps

Public and private peers based on sector, stage, and business model.

AceLink Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AceLink Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	May 1, 2021
Seed	Jul 1, 2019

View all Funding Rounds

AceLink Therapeutics Investors

Notable investors and investment history

AceLink Therapeutics investors
Investor	Rounds
Kaitai Capital	Seed, Series A
Viva BioInnovator	Seed, Series A
Shengshan Asset Management	Seed, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 2, 2026
Monthly visitors increased 111% MoM, reaching 1.5K.
May 2, 2025
Monthly visitors grew 70% MoM, reaching 1K.

View all signals

AceLink Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

AceLink Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AceLink Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewark, California

Employee Range4

Year Founded2018

Last FundingMay 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.